Grey Street Capital’s Pfizer PFE Stock Holding History

Grey Street Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$539K	Buy	19,414 +9,638	+99%	+$267K	0.07%	278
2023 Q4	$281K	Sell	9,776 -379	-4%	-$11.5K	0.13%	108
2023 Q3	$337K	Hold	10,155	–	–	0.19%	88
2023 Q2	$372K	Buy	10,155 +1,800	+22%	+$70.1K	0.2%	81
2023 Q1	$341K	Buy	+8,355	New	+$361K	0.24%	81

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Grey Street Capital's PFE Position: Q1 2024 in Review

Grey Street Capital increased its Pfizer (PFE) stake by 99% in Q1 2024, buying an estimated $267K and bringing the position to 19,414 shares worth $539K. The position accounts for 0.07% of the portfolio, ranked #278.

Grey Street Capital first reported a position in PFE in Q1 2023 and has held it in 5 quarters since. 2,878 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

Grey Street Capital held 19,414 shares of Pfizer worth $539K as of Q1 2024.
Grey Street Capital bought 9,638 Pfizer shares in Q1 2024, an estimated $267K.
Pfizer made up 0.07% of Grey Street Capital's portfolio in Q1 2024, its #278 holding.
Grey Street Capital first reported a position in Pfizer in Q1 2023 and has held it in 5 quarters since.
2,878 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.